CanSino Biologics, Inc. (CASBF)
3.90
0.00 (0.00%)
USD |
OTCM |
Aug 25, 16:00
CanSino Biologics Enterprise Value : 830.34M for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 830.34M |
| August 24, 2026 | 830.34M |
| August 21, 2026 | 830.34M |
| August 20, 2026 | 830.34M |
| August 19, 2026 | 643.82M |
| August 18, 2026 | 643.82M |
| August 17, 2026 | 643.82M |
| August 14, 2026 | 643.82M |
| August 13, 2026 | 643.82M |
| August 12, 2026 | 643.82M |
| August 11, 2026 | 643.82M |
| August 10, 2026 | 643.82M |
| August 07, 2026 | 643.82M |
| August 06, 2026 | 643.82M |
| August 05, 2026 | 643.82M |
| August 04, 2026 | 643.82M |
| August 03, 2026 | 643.82M |
| July 31, 2026 | 643.82M |
| July 30, 2026 | 643.82M |
| July 29, 2026 | 643.82M |
| July 28, 2026 | 643.82M |
| July 27, 2026 | 643.82M |
| July 24, 2026 | 643.82M |
| July 23, 2026 | 643.82M |
| July 22, 2026 | 643.82M |
| Date | Value |
|---|---|
| July 21, 2026 | 643.82M |
| July 20, 2026 | 643.82M |
| July 17, 2026 | 643.82M |
| July 16, 2026 | 509.18M |
| July 15, 2026 | 509.18M |
| July 14, 2026 | 509.18M |
| July 13, 2026 | 509.18M |
| July 10, 2026 | 509.18M |
| July 09, 2026 | 509.18M |
| July 08, 2026 | 509.18M |
| July 07, 2026 | 509.18M |
| July 06, 2026 | 509.18M |
| July 02, 2026 | 509.18M |
| July 01, 2026 | 509.18M |
| June 30, 2026 | 509.18M |
| June 29, 2026 | 509.18M |
| June 26, 2026 | 509.18M |
| June 25, 2026 | 573.41M |
| June 24, 2026 | 573.41M |
| June 23, 2026 | 573.41M |
| June 22, 2026 | 573.41M |
| June 18, 2026 | 573.41M |
| June 17, 2026 | 632.70M |
| June 16, 2026 | 632.70M |
| June 15, 2026 | 632.70M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Sinovac Biotech Ltd. | -210.46M |
| CASI Pharmaceuticals, Inc. | 24.50M |
| Shanghai Junshi Biosciences Co., Ltd. | 3.669B |
| Ascletis Pharma, Inc. | 1.194B |
| CStone Pharmaceuticals Co. Ltd. | 804.85M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.838M |
| Revenue (Quarterly) | 27.48M |
| Total Expenses (Quarterly) | 33.32M |
| EPS Diluted (Quarterly) | -0.0236 |
| Gross Profit Margin (Quarterly) | 80.94% |
| Profit Margin (Quarterly) | -21.24% |
| Earnings Yield | -0.03% |
| Normalized Earnings Yield | -0.0744 |